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Introduction
Gastro-oesophageal reflux (GOR) is the spontaneous 
movement of gastric content into the oesophagus due 
to an inappropriate relaxation of the lower oesophageal 
sphincter. It can occur with or without regurgitation and 
vomiting, and is a normal physiological process that occurs 
in many healthy infants. Often reflux occurs in neonates and 
premature infants,1,2 and does not require treatment unless 
it is accompanied with failure to thrive, respiratory problems 
and infant discomfort.3
By 12-15 months, most GOR cases resolve spontaneously. 
A small percentage of children have symptoms after two 
years of age. According to the Montreal global consensus, 
gastro-oesophageal reflux disease (GORD) results when 
GOR is associated with symptoms and complications.4 
These symptoms or complications can include growth 
faltering, irritability, feeding difficulties, respiratory problems, 
anaemia due to iron deficiency, and haematemesis. This 
is a more serious condition, and requires specialised 
care.5-7 No reliable diagnostic test exists, but intraluminal 
oesophageal pH monitoring can be used.7 GOR and GORD 
can be diagnosed from the patient’s history, a thorough 
clinical evaluation and appropriate anthropometrical 
measurements. The patient’s history should focus on 
frequency of regurgitation per day, type of emesis, and 
volume and frequency of food, especially milk and types 
of food.8
Breastfed vs. formula-fed infants have a similar frequency 
in physiological GOR, although breastfeed infants have 
shorter episodes of reflux. Mothers of breastfed infants who 
present with mild symptoms of reflux should be encouraged 
to continue breastfeeding.7
The aim of this review is to provide a summary of the 
latest information available on GOR and GORD regarding 
the symptoms and treatment of both, as well as available 
formula, and the role of thickened formula in the treatment 
of GORD.
Treatment for uncomplicated GOR and 
GORD
The aim of treatment is to reduce symptoms, to optimise 
growth and development, and to prevent further 
complications. Failure to thrive is a warning sign that GORD 
exists.2 Therefore, regular anthropometric measurements 
are important to ensure optimal weight gain.7 Parental 
reassurance, support and education can be sufficient 
management tools.5-7
However, formula-fed infants with recurrent episodes of 
emesis do not necessarily suffer from GOR or GORD, but 
may suffer from cow’s milk protein sensitivity. These infants 
may benefit from a trial with an extensively hydrolysed infant 
formula for two to four weeks. Overfeeding is another cause 
of regurgitation, and parents should reduce the volume of 
feeds to exclude overfeeding as a possible cause of reflux 
episodes.2
Postural therapy
In the past, prone and lateral positioning was used to reduce 
oesophageal exposure to acid. It has since been proved 
that both positions increase the risk of sudden infant death 
syndrome. Therefore, these methods are not recommended 
as a treatment method for GOR or GORD.2,7
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Drug and surgical treatments for GORD
Drugs that are used to treat GORD include alginate 
combinations, histamine 2 receptor antagonists, proton-
pump inhibitors (PPIs) and antacids. Many of these 
are licensed adult drugs. Gaviscon infant®, an alginate 
combination, is licensed for use from birth, and has 
been proven to be effective in reducing the number of 
regurgitation and emetic episodes for mild GOR. Infants 
who do not respond to alginate combinations and dietary 
changes might benefit from treatment with histamine 2 
receptor antagonists, which are effective in reducing acid 
secretion and esophagitis. However, research regarding the 
use of PPIs is conflicting. Although it is believed that PPIs 
reduce gastric acidity, regardless of age, the overall effect 
on histological aberrations in infants remains unclear.9 
Children who would benefit from anti-reflux surgery include 
those with relapsing GORD due to noncompliance of medical 
treatment or the failure of current medical treatment, those 
with recurrent respiratory problems, long-term dependence 
on pharmacotherapy, and pulmonary aspiration of refluxate. 
Currently, there is considerable debate regarding the use 
of fundoplications. Although laparoscopic fundoplication in 
children is considered to be safe and effective, its efficacy in 
controlling respiratory problems remain unclear.10 
Thickened infant formula
Thickened infant formula and thickening agents have long 
been used as part of a stepwise approach to treating GOR 
and GORD. However, the use thereof remains controversial 
due to lack of conclusive evidence regarding efficacy. 
Current research provides some evidence that the use of 
thickened infant formula is beneficial in reducing GOR and 
GORD symptoms.11,12 However, a systematic review could 
not conclude whether a specific thickening agent, such as 
corn starch or maize flower, locust-bean gum, soy fibre, rice 
starch or carob-bean gum, is more effective than another.12
Efficacy of thickened formula marketed 
as anti-reflux formula 
A review demonstrated some positive effects that anti-reflux 
formula, compared to standard infant formula, has on GOR 
symptoms. These are summarised in Table I.12 However, the 
review reported many limitations, such as overestimation 
and reporting of positive effects by parents and doctors. 
The included trials were also sponsored by manufacturers. 
Thickened formula can lead to a significant increase in 
weight gain. Although this is advantageous when infants 
present with failure to thrive, regular weight monitoring 
is necessary to identify excessive weight gain if used for 
extended periods. Feed volumes may be restricted at each 
feed to prevent undesirable weight gain.12 The review also 
indicates that even though the thickening of food reduce 
some symptoms of GOR, it may still result in adverse events. 
Carob thickeners can increase diarrhoea and allergies, while 
the use of rice-thickened feeds might lead to increased 
coughing. Furthermore, thickening agents may decrease 
the absorption of nutrients, such as carbohydrates, fat, 
calcium, iron, zinc and copper, and alter mucosal and 
endocrine responses.12 
Thickened infant formula for GORD
Evidence regarding the benefits of thickened formula 
is contradictory. Some studies found no effect on the 
frequency of regurgitation episodes or oesophageal 
acid exposure time, while others found that formula with 
corn starch as a thickening agent reduces the frequency 
and severity of reflux and vomiting, and may potentially 
decrease oesophageal acid exposure, as evaluated with pH 
monitoring.13
Table I: The positive effects of different thickening agents on gastro-oesophageal reflux symptoms12
Symptoms of gastro-oesophageal reflux 
Thickener Increase in 
the number of 
infants without 
regurgitation
Decrease 
in vomiting 
episodes 
Decrease in 
regurgitation 
episodes 
Decrease 
in irritability 
episodes 
Decrease in 
crying and 
dysphagia
Decrease in 
regurgitation 
symptoms 
Improvement 
in reflux index
Soy fibre X - X - - - -
Carob-bean gum X - X - - - -
Corn flour - X X - - - -
Rice based - X X - - - -
Locust-bean gum - - X - - - -
Corn-starch - X - X X X -
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Possible adverse effects of using anti-regurgitation 
formula
Reduced caloric density, osmolality, protein, calcium and 
fatty acid content in anti-regurgitation or reflux formula, 
suggest that such formula is more advantageous than a 
standard formula with added thickener.7 It is possible that 
thickening agents may decrease the bioavailability of key 
nutrients by decreasing the intestinal absorption. When 
formula are thickened with indigestible carbohydrates, such 
as carob-bean gum, the bioavailability of calcium, iron and 
zinc is decreased, which is not seen when starch is used.12,13
It is the joint recommendation of the North American Society 
for Pediatric Gastroenterology, Hepatology and Nutrition 
(NASPGHAN) and the European Society for Paediatric 
Gastroenterology, Hepatology and Nutrition (ESPGHAN) 
that the use of thickened formula may decrease visible 
regurgitation, but does not result in a measurable decrease 
in the frequency of oesophageal reflux episodes. ESPGHAN 
and NASPGHAN further recommend that in the absence of 
complicated GOR, the use of a thickened formula might be 
advised. If warning signs and signs of complicated GORD 
(Table II) are present, further investigation is needed.2
Commercially available thickened formula
A number of thickened infant formula is available in South 
Africa (Table III). Thickening agents include soy fibre, carob-
bean gum, corn starch, rice and locust-bean gum. Some 
adverse effects, such as diarrhoea and allergies, have been 
reported with the use of carob thickener, while rice thickener 
was found to increase coughing in infants < 24 months with 
GORD.12
The nutritional composition of all infant formula, including 
anti-reflux formula, must meet the global standards 
Table III. Available anti-regurgitation or reflux formula
Class Brand name Thickening agent 
used
kcal/
100 ml
Protein source and 
g/100 ml
Carbohydrates
and g/100 ml
Additives
Anti-reflux 
formula 
Nan AR® Precooked corn starch 67.0 Demineralised whey
30:70 whey-
dominant, 1.24
Lactose, potato and 
corn starch, 7.7
-
Novalac AR 1®
Novalac AR 2®
Corn starch (thickens 
at gastric pH) 1: 66.0
2: 64.3
Skim milk, 
80:20 casein-
dominant, 1:1.6, 
2:1.7
Lactose and corn 
starch, 7.4
Long-chain 
polyunsaturated fatty 
acids
Novalac AR® 
Digest®
Locus-bean gum and 
starch
62.8 100% partially 
hydrolysed whey, 
1.5
Maltodextrin and 
lactose, 6.8
Long-chain 
polyunsaturated fatty 
acids
Infacare 
Nurture AR®
Carob-bean gum 67.0 Skim milk, 
80:20 casein-
dominant, 1.6
Lactose, maltodextrin, 
corn syrup solids, 7.0
DHAa, AAb, and 
nucleotides
Infacare AR® Locus-bean gum (guar 
gum, a soluble fibre)
66.0 Skim milk, 
80:20 casein-
dominant, 1.6
Lactose, maltodextrin, 
corn syrup solids, 6.8
-
Thickening 
agent
Nestargel® Carob-bean gum
(carob seed flour)
38.0 kcal/
100 g powder
6 g/100 g powder Cellulose 
1 g/100 g
hemicellulose
76.2 g/100 g
-
a = docosahexanoic acid, b = arachidonic acid
Table II: Warning signs and signs of complicated gastro-oesophageal 
reflux disease2
Warning signs Signs of complicated gastro-
oesophageal reflux disease
Bilious vomiting
Gastrointestinal bleeding
Haematemesis
Haematochezia
Consistently forceful vomiting
Onset of vomiting after six 
months of life
Failure to thrive
Diarrhoea
Constipation
Fever
Lethargy
Hepatosplenomegaly
Bulging fontanelles
Macrocephaly or microcephaly
Seizures
Abdominal tenderness or 
distension
Documented or suspected 
genetic or metabolic syndrome
Oesophagitis
Oesophageal stricture
Barrett’s oesophagus
Laryngeal or pharyngeal 
inflammation
Recurrent pneumonia
Anaemia
Dental erosion
Feeding refusal
Dystonic neck posturing 
(Sandifer syndrome)
Apnoea
Apparent life-threatening events
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recommended by ESPGHAN. Anti-reflux formula is either 
cow-milk-based or hydrolysed cow-milk protein, and must 
contain 1.8-3 g/100 kCal. Soy protein is not indicated for 
use in anti-reflux formula.14
Conclusion
Gastro-oesophageal reflux is a common and normal 
physiological process that affects many infants, especially 
premature infants and neonates. Most cases resolve 
without treatment, but a few might need medical treatment; 
either pharmacotherapy or surgery. Thickened formula 
is often used as a first step in treating complicated GOR. 
The efficacy and efficiency of these are still debatable, but 
many parents and physicians find that it is an effective 
treatment method for mild GOR and GORD. ESPGHAN 
and NASPGHAN have defined guidelines with regard to the 
use of thickened formula, but they should not be seen as a 
substitute for clinical judgment or protocols that are already 
in place at healthcare institutions. More research is needed 
to define clear clinical guidelines on the use of thickened 
infant formula. Research is also needed to compare the use 
of thickened infant formula to that of pharmacotherapy and 
surgical treatment.
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